

# Your blood has a lot to say

Discover more about LucentAD p-Tau 217 to aid in the diagnosis of Alzheimer's Disease





# What is LucentAD p-Tau 217?

LucentAD p-Tau 217 is a simple blood test to help identify if a patient with mild cognitive impairment (MCI) symptoms is likely or unlikely to have amyloid plaques in the brain, a primary indicator of Alzheimer's Disease. Results from the test can provide information to aid in earlier diagnosis, which can help you and your healthcare team determine the best management and treatment strategies for you.

PATIENT GUIDE 3



### Why p-Tau 217?

p-Tau 217 has emerged as a top performing biomarker for Alzheimer's pathology, helping doctors detect the disease accurately in patients experiencing memory loss. Traditional diagnostic methods include positron emission tomography (PET) or lumbar puncture for cerebrospinal fluid (CSF). These tests are often expensive, invasive, and can take an extended period of time to be completed and interpreted. Lucent Diagnostics has evidence to support that the performance of LucentAD p-Tau 217 is comparable to commonly used CSF biomarkers for confirmation of amyloid pathology, without invasive collection or patient recovery time.

## Who is LucentAD p-Tau 217 for?

Lucent AD p-Tau 217 is intended for patients who exhibit symptoms of early AD and mild cognitive impairment, who are undergoing cognitive evaluation by a healthcare provider. The test can only be ordered by a healthcare provider and is used to aid in the diagnosis of Alzheimer's Disease.

## What Are the Benefits of LucentAD p-Tau 217 Testing?

The more you and your provider know about your brain health, the better prepared you'll both be to make healthcare decisions for you and your family.





#### PATIENT PROFILE Patients experiencing mild cognitive impairment or early AD

UTILITY Aid in the early diagnosis of the estimated 6.7 million Americans living with AD<sup>1</sup>



PATIENT PROFILE Patients diagnosed with Alzheimer's Disease, considering treatment options

#### UTILITY

Performance comparable to commonly used cerebrospinal fluid tests for confirmation of amyloid pathology



PATIENT PROFILE Patients at high risk for adverse events from PET and/or CSF testing

#### UTILITY

An alternative, non-invasive method to provide data for patients with iodine intolerance, coagulation disorders, or signs of spinal cord compression<sup>2</sup>



# How to Get Started In 3 Simple Steps



#### Your healthcare provider orders LucentAD p-Tau 217 blood test



#### You provide a blood sample

Test Report	
=	

# Your healthcare provider will review your results with you



Not sure if your provider offers LucentAD p-Tau 217?

Scan the code for more information.



CustomerService@LucentDiagnostics.com


(978) 488.1869

# When Will I Get My Results?

Results are typically available approximately **10 days** after we receive your blood sample at the Lucent Diagnostic laboratory. Your healthcare provider will receive a test report from the laboratory and will review your results together with you.

# How Will My Sample Be Collected?

A certified phlebotomist will collect a single tube of blood from you. In many cases, this will be done in your healthcare provider's office. To learn more about your blood sample collection, please speak with your healthcare provider or you may contact our Customer Service team.



# How Much Will LucentAD p-Tau 217 Cost?

This test is new and is not currently covered by commercial insurance, Medicare, or Medicaid. Lucent Diagnostics is currently pursing payer coverage. In the meantime, we will work with the patient to offer affordable payment options.

# **Patient Assistance**

Lucent Diagnostics works with the patients to ensure affordability. Payment terms are based on the patient's income, expenses, and family size.



Not sure if your provider offers LucentAD p-Tau 217?

的复数使用的复数形式 计正式通信数量的控制

Scan the code for more information.

CustomerService@LucentDiagnostics.com

## (978) 488.1869

References 1. Alzheimer's Association Facts & Figures 2022 2. NIH.gov

